Advertisement
JNJ vs PFE
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- JNJ has delivered stronger year-to-date and one-year returns compared to PFE, reflecting robust momentum in diversified healthcare segments.
- PFE offers a significantly higher dividend yield, appealing to income-focused investors amid its recovery phase.
- Both companies operate in the healthcare sector with exposure to pharmaceuticals, though JNJ benefits from broader medtech and consumer health diversification.
- Recent market activity shows JNJ maintaining relative stability near all-time highs, while PFE exhibits higher volatility tied to pipeline developments.
- Valuation metrics indicate JNJ trades at a premium, supported by consistent earnings quality, whereas PFE presents a more attractive forward earnings multiple.
- Sector sentiment remains constructive for both amid ongoing innovation in oncology and infectious disease treatments.
Introduction
Johnson & Johnson (JNJ) and Pfizer (PFE) represent two established leaders in the global healthcare industry, making them natural subjects for comparative analysis. This stock comparison examines their relative performance, business models, and positioning in the current market environment. The review is relevant for institutional and retail investors seeking exposure to large-cap pharmaceutical and medtech names, as well as traders monitoring sector rotation and dividend strategies. By focusing on verifiable metrics from recent market activity, the analysis highlights trade-offs without offering forward-looking predictions.
JNJ Overview and Recent Performance
Johnson & Johnson operates across pharmaceuticals, medical devices, and consumer health products, providing diversified revenue streams. In recent weeks, the stock has traded near elevated levels following a period of gains driven by oncology advancements and medtech updates. Market activity reflects steady institutional interest, with the shares demonstrating resilience amid broader healthcare sector movements. Positive developments in pipeline assets, including lung cancer therapies, have supported sentiment, while the company maintains a conservative balance sheet profile. Overall, recent performance underscores consistent execution across its segments.
PFE Overview and Recent Performance
Pfizer focuses primarily on biopharmaceuticals, with emphasis on vaccines, oncology, and internal medicine. In recent weeks, the stock has shown recovery momentum from earlier lows, influenced by pipeline progress and cost management initiatives. Trading volumes remain elevated, reflecting ongoing investor attention to upcoming catalysts. The company continues to navigate post-pandemic revenue normalization, with sentiment shaped by earnings stability and dividend consistency. Recent market activity indicates measured optimism tied to operational adjustments.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. Bots feature varied trading styles, strategies, timeframes, and performance statistics, enabling users to match approaches to individual objectives. Available metrics often include historical win rates, drawdown ranges, and ticker-specific results that highlight adaptability. This resource provides traders with data-driven options for automated strategies. Explore the Trending AI Robots page for current selections.
Head-to-Head Comparison
Johnson & Johnson (JNJ) maintains a diversified business model spanning multiple healthcare verticals, contrasting with Pfizer’s (PFE) concentrated biopharmaceutical focus. Growth drivers for JNJ include steady medtech contributions and oncology innovation, while PFE relies on vaccine portfolios and new therapeutic approvals. Recent momentum favors JNJ in total return metrics, though PFE offers superior current income through its dividend. Risk factors differ: JNJ faces litigation and integration considerations, whereas PFE contends with revenue concentration risks. Sector exposure overlaps in healthcare, yet market sentiment appears more anchored for the larger, more stable JNJ profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to Johnson & Johnson (JNJ) over Pfizer (PFE). Stronger momentum and diversified revenue sources contribute to this assessment, though outcomes remain subject to evolving market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and PFE is a StrongBuy.
JNJ | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 37 | 83 | |
PRICE GROWTH RATING 1..100 | 46 | 50 | |
P/E GROWTH RATING 1..100 | 10 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is in the same range as PFE (20). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
JNJ's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as PFE (50). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as JNJ (10). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 57% |
| Stochastic ODDS (%) | 1 day ago 44% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 43% | 1 day ago 50% |
| MACD ODDS (%) | 1 day ago 38% | 1 day ago 47% |
| TrendWeek ODDS (%) | 1 day ago 39% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 50% |
| Advances ODDS (%) | 2 days ago 47% | 2 days ago 54% |
| Declines ODDS (%) | 7 days ago 40% | 14 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 39% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 47% | 1 day ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 4 bearish.
- PFE’s TA Score: 5 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -0.60% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.83% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.68%. For the same industry, the average monthly price growth was -4.26%, and the average quarterly price growth was +11.25%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 13, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.68% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | N/A | ||
| BMY - PFE | 57% Loosely correlated | -1.60% | ||
| MRK - PFE | 55% Loosely correlated | +0.40% | ||
| AMGN - PFE | 52% Loosely correlated | +1.32% | ||
| BIIB - PFE | 48% Loosely correlated | -0.71% | ||
| NVS - PFE | 48% Loosely correlated | -0.80% | ||
More | ||||